| Ticker: | STTK |
| Current Price: | $4.65 |
| % Daily Change: | -3.33% |
| Volume (1,000s): | 775.90 |
| Average Volume (1,000s): | 1,237.91 |
| Market Cap (M): | $473.57 |
| 1/2/2024 Price: | $7.56 |
| Change Since Inception: | -38.49% |
Shattuck Labs, Inc.
500 West 5th Street
Suite 1200
Austin, TX 78701
United States
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.